• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications are not effective for a lot of patients suffering from postpartum depression natural treatment. The individual approach to treatment could be the answer.

Cue is a digital intervention platform that translates passively acquired normal sensor data from smartphones into customized micro-interventions to improve mental health. We analyzed the best-fitting personalized ML models to each person using Shapley values, in order to understand their feature predictors. This revealed distinct features that changed mood in a predictable manner over time.

Predictors of Mood

Depression is one of the leading causes of mental illness.1 However, only half of those who have the disorder receive treatment1. In order to improve outcomes, doctors must be able to recognize and treat patients who have the highest probability of responding to certain treatments.

Personalized depression treatment can help. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit most from specific treatments. They make use of sensors on mobile phones and a voice assistant incorporating artificial intelligence as well as other digital tools. Two grants totaling more than $10 million will be used to identify the biological and behavioral factors that predict response.

So far, the majority of research on factors that predict depression treatment effectiveness has been focused on sociodemographic and clinical characteristics. These include demographics like gender, age and education as well as clinical aspects like severity of symptom and comorbidities, as well as biological markers.

While many of these variables can be predicted by the information available in medical records, few studies have employed longitudinal data to explore the factors that influence mood in people. Many studies do not take into account the fact that mood can be very different between individuals. Therefore, it is important to develop methods which allow for the determination and quantification of the individual differences between mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can identify different patterns of behavior and emotions that differ between individuals.

The team also devised an algorithm for machine learning to create dynamic predictors for each person's mood for depression. The algorithm blends the individual characteristics to create a unique "digital genotype" for each participant.

This digital phenotype was associated with CAT DI scores, a psychometrically validated symptom severity scale. The correlation was not strong, however (Pearson r = 0,08; P-value adjusted by BH 3.55 10 03) and varied greatly between individuals.

Predictors of symptoms

Depression is a leading cause of disability in the world1, but it is often not properly diagnosed and treated. Depressive disorders are often not treated due to the stigma that surrounds them and the absence of effective treatments.

To allow for individualized treatment to improve treatment, identifying the patterns that can predict symptoms is essential. However, the current methods for predicting symptoms are based on the clinical interview, which is not reliable and only detects a small number of features that are associated with depression.2

Machine learning can increase the accuracy of the diagnosis and treatment of depression by combining continuous, digital behavioral phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes are able to are able to capture a variety of unique behaviors and activities that are difficult to capture through interviews and permit continuous and high-resolution measurements.

The study involved University of California Los Angeles (UCLA) students who were suffering from mild to severe depression symptoms. who were enrolled in the Screening and Treatment for Anxiety and depression private treatment (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical treatment according to the severity of their depression. Those with a score on the CAT DI of 35 or 65 were assigned online support via a coach and those with scores of 75 patients were referred to in-person psychotherapy.

At baseline, participants provided an array of questions regarding their personal characteristics and psychosocial traits. These included sex, age and education, as well as work and financial situation; whether they were partnered, divorced or single; their current suicidal thoughts, intentions or attempts; and the frequency with which they drank alcohol. Participants also scored their level of depression symptom severity on a scale of 0-100 using the CAT-DI. The CAT DI assessment was carried out every two weeks for participants who received online support, and weekly for those who received in-person assistance.

Predictors of Treatment Response

Research is focusing on personalization of treatment for depression. Many studies are focused on identifying predictors, which will help clinicians identify the most effective drugs to treat each patient. Pharmacogenetics, in particular, is a method of identifying genetic variations that affect the way that our bodies process drugs. This allows doctors to select the medications that are most likely to be most effective for each patient, minimizing the time and effort in trial-and-error treatments and avoiding side effects that might otherwise hinder advancement.

Another promising approach is building models of prediction using a variety of data sources, combining the clinical information with neural imaging data. These models can then be used to identify the best combination of variables that is predictors of a specific outcome, such as whether or not a drug will improve symptoms and mood. These models can be used to determine a patient's response to treatment that is already in place which allows doctors to maximize the effectiveness of current therapy.

A new type of research uses machine learning methods such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of multiple variables to improve predictive accuracy. These models have been proven to be effective in the prediction of treatment outcomes like the response to antidepressants. These techniques are becoming increasingly popular in psychiatry and could become the norm in the future treatment.

The study of depression's underlying mechanisms continues, in addition to predictive models based on ML. Recent findings suggest that the disorder is linked with neural dysfunctions that affect specific circuits. This theory suggests that a individualized treatment for depression will be based upon targeted treatments that restore normal function to these circuits.

Internet-delivered interventions can be a way to accomplish this. They can offer a more tailored and individualized experience for patients. One study found that a web-based program improved symptoms and led to a better quality of life for MDD patients. Furthermore, a randomized controlled study of a personalised approach to treating depression (visit the following website) showed an improvement in symptoms and fewer adverse effects in a large proportion of participants.

Predictors of Side Effects

A major issue in personalizing depression treatment involves identifying and predicting which antidepressant medications will cause the least amount of side effects or none at all. Many patients are prescribed a variety drugs before they find a drug that is effective and tolerated. Pharmacogenetics offers a fresh and exciting method of selecting antidepressant medications that is more effective and precise.

Several predictors may be used to determine which antidepressant is best to prescribe, including genetic variations, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and comorbidities. To identify the most reliable and reliable predictors for a specific treatment, randomized controlled trials with larger samples will be required. This is due to the fact that the identification of interactions or moderators can be a lot more difficult in trials that only focus on a single instance of treatment per person, rather than multiple episodes of treatment over a period of time.

Additionally, the prediction of a patient's reaction to a specific medication will also likely require information about comorbidities and symptom profiles, as well as the patient's personal experience with tolerability and efficacy. Presently, only a handful of easily measurable sociodemographic and clinical variables appear to be reliably associated with response to MDD factors, including gender, age race/ethnicity, SES, BMI and the presence of alexithymia, and the severity of depression and anxiety treatment near me symptoms.

The application of pharmacogenetics to treatment for depression is in its early stages and there are many obstacles to overcome. First, it is important to have a clear understanding and definition of the genetic mechanisms that underlie depression, and an accurate definition of a reliable indicator of the response to treatment. Ethics like privacy, and the ethical use of genetic information must also be considered. Pharmacogenetics can eventually help reduce stigma around mental health treatments and improve the outcomes of treatment. As with all psychiatric approaches it is essential to carefully consider and implement the plan. At present, it's best antidepressant for treatment resistant depression to offer patients an array of depression medications that are effective and urge patients to openly talk with their doctor.